Clinicians need critical diagnostics earlier to empower the best, actionable care pathways.
Empowered clinicians give millions the opportunity of timely treatment and improved patient outcomes.
Is to bring trusted diagnostics to the point of initial patient interaction, to expand access of quality healthcare to new settings, no matter where that patient interaction occurs
Timely Host Response Diagnostics for SEPSIS and Pneumonia
*The Nanōmix eLab® S1 Panel for Critical Infection has received CE Mark; other assays in development and regulatory review.
We are very pleased to report CE mark designation in Europe for our S1 assay panel using a whole blood sample type
Upgrading to the OTCQB is a timely and important milestone for Nanōmix, as we continue to commercialize our Nanōmix eLab® system, a mobile point-of-care diagnostic testing platform.
Receiving the CE mark for our COVID-19 rapid antigen test is a key milestone which further validates our rapid and accurate point-of-care (POC) testing technology.
Relocates Headquarters and Labs to a Larger Facility while Reducing Overhead Expense.
GHS Investments, LLC (GHS) is a leading private investment and management group.
